CRPC w/ Bone Metastases

Targeted Alpha Therapy, an Emerging Class of Cancer Agents - A Review September 21, 2018

Microscopic Imaging Pierces the “Black Box” of Cancer Bone Metastasis August 1, 2018

Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial. May 17, 2018

Radiation for Treatment of Painful Bone Metastases. May 15, 2018

Safety and efficacy of radium-223 dichloride in Japanese patients with castration-resistant prostate cancer and bone metastases. March 20, 2018

Radium-223 for primary bone metastases in patients with hormone-sensitive prostate cancer after radical prostatectomy. March 20, 2018

Optimal usage of radium-223 in metastatic castration-resistant prostate cancer. March 14, 2018

The Contemporary Use of Radium-223 in Metastatic Castration-resistant Prostate Cancer. March 14, 2018

Radium-223 international early access program: results from the Spanish subset. March 14, 2018

Utility of F-18 FDG PET/CT for Detection of Bone Marrow Metastases in Prostate Cancer Patients Treated with Radium-223. March 14, 2018

Impact of treatment delay in Radium-223 therapy of metastatic castration-resistant prostate cancer patients. March 12, 2018

Launch of Oncotype DX® AR-V7 Nucleus Detect™ Test Expands Offering to Prostate Cancer Patients - Predicting Treatment Response in Metastatic Disease February 26, 2018

Current approaches to incorporation of radium-223 in clinical practice. January 9, 2018

Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer January 8, 2018

Understanding the Progression of Bone Metastases to Identify Novel Therapeutic Targets. January 8, 2018

Re-treatment with radium-223: first experience from an international, open-label, phase I/II study in patients with castration-resistant prostate cancer and bone metastases. October 1, 2017

Targeted alpha therapy of mCRPC: Dosimetry estimate of (213)Bismuth-PSMA-617. September 18, 2017

Radium-223 therapy of advanced metastatic castration-resistant prostate cancer: quantitative assessment of skeletal tumor burden for prognostication of clinical outcome and hematological toxicity. September 6, 2017

Radium-223 for primary bone metastases in patients with hormone-sensitive prostate cancer after radical prostatectomy. September 6, 2017

Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial. July 15, 2017

Page 1 of 9

E-Newsletters

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

CRPC w/ Bone Metastases

Free Daily and Weekly newsletters offered by content of interest

Login